Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 5/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3963496 | 0.95 | NR3C1 (0.57) | NR3C1KMT2APOLBMAPTMEN1 | |
| SCHEMBL3960771 | 0.86 | KMT2A (0.53) | NR3C1KMT2APOLBALDH1A1CYP1A2 | |
| SCHEMBL3969322 | 0.84 | KMT2A (0.48) | NR3C1KMT2APOLBALDH1A1CYP1A2 | |
| SCHEMBL3966943 | 0.83 | KMT2A (0.50) | NR3C1KMT2APOLBALDH1A1CYP1A2 | |
| SCHEMBL3970562 | 0.83 | KMT2A (0.50) | NR3C1KMT2APOLBALDH1A1CYP1A2 | |
| SCHEMBL29200760 | 0.81 | MAPT (0.55) | NR3C1KMT2APOLBALDH1A1MAPT | |
| SCHEMBL3967546 | 0.81 | NR3C1 (0.67) | NR3C1LMNAMAPT | |
| SCHEMBL3964519 | 0.81 | NR3C1 (0.55) | NR3C1KMT2APOLBLMNAMAPT | |
| SCHEMBL3971896 | 0.80 | NR3C1 (0.52) | NR3C1KMT2AALDH1A1LMNAMEN1 | |
| SCHEMBL3965867 | 0.79 | KMT2A (0.46) | NR3C1KMT2APOLBALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1363876-B1 | GLUCOCORTICOID RECEPTOR MODULATORS | KAROBIO AB (SE) | 2009-07-29 | — | — | EP | disclosed |
| EP-1363876-A1 | GLUCOCORTICOID RECEPTOR MODULATORS | Abbott Laboratories (US) | 2003-11-26 | — | — | EP | disclosed |
| US-6583180-B2 | Antidiabetic agents | ABBOTT LABORATORIES | 2003-06-24 | — | — | US | disclosed |
| US-20020156311-A1 | Glucocorticoid receptor modulators | KARO BIO AB (SE) | 2002-10-24 | — | — | US | disclosed |
| WO-2002064550-A1 | GLUCOCORTICOID RECEPTOR MODULATORS | ABBOTT LABORATORIES (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156311-A1 | Glucocorticoid receptor modulators | NR3C1, NR5A1, NR3C2 | NR3C1 1/4885KMT2A 4447/4885POLB 4279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.